ATHA Projected Dividend Yield

Athira Pharma Inc ( NASDAQ : ATHA )

Athira Pharma is a late clinical-stage biopharmaceutical company. Co.'s primary candidate, fosgonimeton (ATH-1017), is a blood brain barrier-penetrating, small molecule hepatocyte growth factor (HGF)/MET positive modulator. The primary target indication is Alzheimer's disease (AD). Co.'s product candidate for its neuropsychiatric program is ATH-1020, which is a small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and to distribute to the central nervous system. Co. has several preclinical candidates for non-AD indications, including ATH-1019, which is being developed to address peripheral indications such as peripheral neuropathy.

20 YEAR PERFORMANCE RESULTS